QUOTE AND NEWS
Benzinga  Apr 24  Comment 
Tranzyme Pharma (NASDAQ: TZYM) and Ocera Therapeutics, Inc. ("Ocera"), a privately held biopharmaceutical company developing novel therapeutics for liver diseases, today announced that they have entered into a definitive agreement under which...
StreetInsider.com  Mar 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Tranzyme%2C+Inc.+%28TZYM%29+Tops+Q4+EPS+by+12c/8218730.html for the full story.
FierceBiotech  Feb 8  Comment 
After key clinical trials failed last year, troubled Tranzyme ($TZYM) is seeking "strategic alternatives" for its business. On the table are potential options such as a merger or company sale--anything to bring value to shareholders.   The...
Benzinga  Feb 8  Comment 
Tranzyme (NASDAQ: TZYM) announced today that its Board of Directors has made a determination to explore and evaluate strategic alternatives, including the possibility of a merger, sale, other form of business combination, or other transaction to...
Benzinga  Jan 15  Comment 
Tranzyme Pharma (NASDAQ: TZYM) today announced that David S. Moore has been named as Chief Business Officer. "Dave has provided meaningful contributions and leadership since joining Tranzyme said Vipin Garg, PhD, Tranzyme's President and Chief...
Benzinga  Jan 4  Comment 
Tranzyme Pharma (NASDAQ: TZYM) today announced the successful completion of its chemistry-based drug discovery collaboration with Bristol-Myers Squibb (NYSE: BMY). As a result of the joint research efforts, Tranzyme has transferred compounds to...
FierceBiotech  Dec 17  Comment 
Research Triangle Park, NC-based Tranzyme ($TZYM) offered another bitter pill for its investors today. The biotech says it is discontinuing a Phase IIb study of its lead drug for diabetic patients suffering from gastroparesis after concluding that...
StreetInsider.com  Dec 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Tranzyme+%28TZYM%29+Halts+TZP-102+Phase+2b%3B+Cites+Insufficient+Efficacy/7951901.html for the full story.
StreetInsider.com  Dec 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Tranzyme+%28TZYM%29+CFO+Eisenstadt+Resigns/7926990.html for the full story.
Benzinga  Nov 16  Comment 
In a report published Friday, Canaccord Genuity downgraded its rating on Tranzyme (NASDAQ: TZYM) from Buy to Hold, and lowered its price target from $7 to $1.50. Canaccord Genuity noted, “Lowering to HOLD, decreasing target to $1.50 on...




 
TOP CONTRIBUTORS

Tranzyme (NASDAQ:TZYM) is a biopharmaceutical company which is developing treatments for gastrointestinal motility disorders. Tranzyme's lead drug, ulimeroelin, is in Phase 3 of clinical trials while its second drug is in Phase 2b. The drugs are designed to treat both chronic and accute gastrointestinal (GI) motility disorders, which are disorders where the normal movement of food through ones GI tract are disrupted. Tranzyme estimates that approximately 20% of adults worldwide have symptoms which would be treated by their drug candidates.[1]

In June 2010, Tranzyme entered into a license agreement with a GI-focused pharmaceutical company called Norgine. The agreement gives Norgine exclusive rights to sell ulimorelin, the Phase 3 drug, in Europe, Australia, New Zealand, Middle East, North Africa, and South Africa. In return, Norgine will sahre the costs of the Phase 3 trials and Tranzyme will receive milestone payments and royalties from Norgine's sales.[2]

The company's initial public offering of stock on the NASDAQ occurred on April 1, 2011. The company offered 13.5 shares each for $4. This was far below the initial price range of $11-$13. The company had originally planned to sell 5M shares, but drastically increased the offer size to match drop in price. The total offering was supposed to raise $60M, but price changed combined with drop in size offering brought the total deal to $54M. The lead underwriter of the deal was Citigroup (C).[3]

Tranzyme is largely pre-revenue since it does not have any commercially available products yet. However, the company has made money through its license agreements and through funding for research. As a result, Tranzyme's total revenue in 2010 was $8.5M. This was a substantial increase over the 2009 total revenue of $.7M. The company reported a net less of $7.3M in 2010 and $11.2M in 2009. Things brings the company's total accumulated deficit to approximately $84.4M in 2010.[4]

References

  1. TZYM 2011 S-1/A PROSPECTUS SUMMARY "Tranzyme, Inc." pg 1
  2. TZYM 2011 S-1/A PROSPECTUS SUMMARY "Our Strategic Partnerships" pg 2
  3. Renaissance Capital - IPO Home "Tranzyme prices IPO at $4, well below the original $11-$13 range" 1 April 2011
  4. TZYM 2011 S-1/A PROSPECTUS SUMMARY "Summary Financial Data" pg 7-8
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki